The notices it replaced
- Reissues: PAR-22-089 Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)
- 2 steps back: PAR-19-315 Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)
Who won it before
25 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $24,144,245 in first-year total cost, median $824,668.
Most frequent study sections
- Neurological Sciences and Disorders A Study Section[NSD-A]14
- Neurological Sciences and Disorders B Study Section[NSD-B]11
Most frequent institutions
- MASSACHUSETTS GENERAL HOSPITAL3
- BOSTON CHILDREN'S HOSPITAL2
- ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER2
- BOSTON UNIVERSITY MEDICAL CAMPUS1
- BRIGHAM AND WOMEN'S HOSPITAL1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Advancing a Prognostic and Monitoring Biomarker of Neutrophil-driven Secondary Brain Injury in Spontaneous Intracerebral Hemorrhage for Neurotherapeutics Development1R61NS135285-01A1 · under PAR-22-089 | GREER, DAVID MATTHEWHERRERA, VICTORIA L | BOSTON UNIVERSITY MEDICAL CAMPUS, MA | $704,313 | NSD |
| 2024 | Discovery and validation of multi-omic plasma biomarkers for Adrenomyeloneuropathy1R61NS131928-01A1 · under PAR-22-089 | FATEMI, S. ALISINGH, JASPREET | HUGO W. MOSER RES INST KENNEDY KRIEGER, MD | $829,626 | NSD |
| 2024 | Development and Validation of a Nocturnal Sleep Signature for the Diagnosis of Idiopathic Hypersomnia1R61NS130215-01A1 · under PAR-22-089 | MASKI, KIRAN PRASAD | BOSTON CHILDREN'S HOSPITAL, MA | $785,153 | NSD |
| 2023 | Biomarkers to Predict Outcome from Responsive Brain Stimulation for Epilepsy1R61NS125568-01A1 · under PAR-19-315 | DAVIS, KATHRYN ADAMIAK | UNIVERSITY OF PENNSYLVANIA, PA | $1,299,779 | NSD |
| 2023 | Development of Translatable Neurophysiological Biomarkers to Accelerate Therapeutic Development in Rett Syndrome1R61NS130216-01 · under PAR-19-315 | MARSH, ERIC DNEUL, JEFFREY L | CHILDREN'S HOSP OF PHILADELPHIA, PA | $941,744 | NSD |
| 2023 | Electrographic Seizure Pattern Modulation Biomarkers in Responsive Neurostimulation for Epilepsy1R61NS126776-01A1 · under PAR-22-089 | RICHARDSON, ROBERT MARK | MASSACHUSETTS GENERAL HOSPITAL, MA | $836,917 | NSD |
| 2023 | Diffusion MRI Biomarkers of Peripheral Nerve Trauma1R61NS127268-01A1 · under PAR-19-315 | DORTCH, RICHARDMAHAN, MARKTHAYER, WESLEY P | ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER, AZ | $824,668 | NSD |
| 2023 | Subtype-Selective Metabotropic Glutamate Receptor PET Ligands1R61NS130128-01 · under PAR-19-315 | LIANG, STEVEN H | EMORY UNIVERSITY, GA | $816,387 | NSD |
| 2023 | tRNA-derived RNA Fragments (tRF) as Prognostic and Diagnostic Biomarkers for Alzheimer’s Disease1R61AG075725-01A1 · under PAR-19-315 | BAO, XIAOYONGFANG, XIANG | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $799,998 | NSD |
| 2023 | Sensory Amplifications as Biomarkers of Migraine Progression1R61NS125153-01A1 · under PAR-19-315 | BRENNAN, KEVIN CHRISTOPHER | UNIVERSITY OF UTAH, UT | $750,148 | NSD |
| 2023 | Pharmacodynamic Biomarker of Myotonic Dystrophy1R61NS131932-01 · under PAR-22-089 | HAMEL, JOHANNATHORNTON, CHARLES A | UNIVERSITY OF ROCHESTER, NY | $421,172 | NSD |
| 2022 | Discovery and Validation of a Novel Response Biomarker Signature for Painful Peripheral Neuropathy1R61NS122298-01A1 · under PAR-19-315 | NEMENOV, MIKHAIL I.SINGLETON, JOHN ROBINSON | LASMED, LLC, CA | $1,000,168 | NSD |
| 2022 | Consortium Of MRI Biomarkers In Neonatal Encephalopathy (COMBINE)1R61NS126792-01 · under PAR-19-315 | GRANT, PATRICIA ELLENLAPTOOK, ABBOT ROU, YANGMING | BOSTON CHILDREN'S HOSPITAL, MA | $942,614 | NSD |
| 2022 | Relaxivity Contrast Imaging as Biomarker of Muscle Degeneration in ALS1R61NS119642-01A1 · under PAR-19-315 | QUARLES, CHRISTOPHER CHAD | ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER, AZ | $809,219 | NSD |
| 2022 | Discovery of Plasma Biomarkers of Delayed Cerebral Ischemia after Subarachnoid Hemorrhage1R61NS119640-01A1 · under PAR-19-315 | CHOI, HUIMAHN ALEXSAVARRAJ, JUDE PJ | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $655,819 | NSD |
| 2022 | Biomarker Signatures for Duchenne Muscular Dystrophy1R61NS119639-01A1 · under PAR-19-315 | DANG, UTKARSH JHATHOUT, YETRIB | STATE UNIVERSITY OF NY,BINGHAMTON, NY | $515,364 | NSD |
| 2022 | Biomarker development in patients with HNPP1R61NS119434-01A1 · under PAR-19-315 | CHEN, YONGSHENGLI, JUN | WAYNE STATE UNIVERSITY, MI | $472,230 | NSD |
| 2022 | Intracranial D-2-Hydroxyglutarate as a Monitoring Biomarker for IDH-mutant Glioma.1R61NS122096-01A1 · under PAR-19-315 | BURNS, TERRY | MAYO CLINIC ROCHESTER, MN | $397,500 | NSD |
| 2021 | Identification and Verification of S-Nitrosylated Proteins in Bodily Fluids as Biomarkers for Parkinson's Disease and Lewy Body Dementia1R61NS122098-01 · under PAR-19-315 | NAKAMURA, TOMOHIRO | SCRIPPS RESEARCH INSTITUTE, THE, CA | $2,199,931 | NSD |
| 2021 | Extracellular RNA biomarkers of myotonic dystrophy type 11R61NS117210-01A1 · under PAR-19-315 | WHEELER, THURMAN M | MASSACHUSETTS GENERAL HOSPITAL, MA | $2,126,281 | NSD |
| 2021 | Plasma metabolite and proteome signatures for migraine classification1R61NS122074-01 · under PAR-19-315 | CHASMAN, DANIEL IANRIST, PAMELA M. | BRIGHAM AND WOMEN'S HOSPITAL, MA | $2,065,041 | NSD |
| 2021 | Biomarker Signatures for Delayed Cerebral Ischemia and Outcome Following Subarachnoid Hemorrhage1R61NS119345-01 · under PAR-19-315 | ANDER, BRADLEY PEARCESHARP, FRANK RSTAMOVA, BORYANA | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $681,385 | NSD |
| 2020 | Objective tests utilizing Vibrational Spectroscopy for Diagnosis and Severity of Fibromyalgia and Related Pain Syndromes1R61NS117211-01 · under PAR-19-315 | HACKSHAW, KEVIN VICTORRODRIGUEZ-SAONA, LUIS E | UNIVERSITY OF TEXAS AT AUSTIN, TX | $1,466,498 | NSD |
| 2020 | Plasma MicroRNA Biomarkers to Guide Rehabilitation Therapy After Stroke1R61NS117196-01 · under PAR-19-315 | EDWARDSON, MATTHEW A | GEORGETOWN UNIVERSITY, DC | $969,858 | NSD |
| 2020 | Molecular imaging of RIPK1/necroptosis as a key biomarker in Alzheimer's disease1R61AG067916-01 · under PAR-19-315 | WANG, CHANGNINGZHANG, CAN MARTIN | MASSACHUSETTS GENERAL HOSPITAL, MA | $832,432 | NSD |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.